Emtricitabine with tenofovir disoproxil



Temporary brand change from Viatris to Teva

Due to a delay in the shipment of emtricitabine with tenofovir disoproxil, you are getting the Teva brand of medicine.

Slightly different formulation

The Teva product contains a different salt form of tenofovir disoproxil compared to the Viatris product.

The Teva tenofovir disoproxil 245 mg works as well as the Viatris tenofovir disoproxil maleate 300 mg.

The medicine works the same way

Medsafe has approved the Teva brand. They have reviewed test results and confirmed that the Teva brand and Viatris brand both work the same way.

You might be familiar with the Teva brand. It has been funded before in New Zealand.

Take it the same way

You take the Teva tablet the same way you would take take the Viatris product.

Your usual brand will be back

Viatris, the supplier, expects to have their product available again in January 2025.

Stay up-to-date

See Pharmac's website for more information.

www.pharmac.govt.nz/etd

About us

Pharmac is the New Zealand Government Agency that makes decisions about what medicines are funded for use in New Zealand.

Email: enquiry@pharmac.govt.nz

